Sort   by:  
 Page size 
UnknownNivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study.
Not available
S-EPMC5946731 | biostudies-literature
UnknownPhase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma.
Not available
S-EPMC4879709 | biostudies-literature
UnknownSurvival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.
Not available
S-EPMC4811023 | biostudies-literature
UnknownSurvival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab.
Not available
S-EPMC4517051 | biostudies-literature
UnknownOverall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.
Not available
S-EPMC4672027 | biostudies-literature
UnknownLong-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib.
Not available
S-EPMC10466457 | biostudies-literature
UnknownOverall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial.
Not available
S-EPMC6804912 | biostudies-literature
UnknownEfficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis.
Not available
S-EPMC5559888 | biostudies-literature
UnknownCombined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor.
Not available
S-EPMC4226803 | biostudies-literature
Sort   by:  
 Page size